Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling

June 1, 2015
Authors: Zuckermann, et al.
B-MoGen Authors: Branden Moriarity & David Largaespada
Publication: Nature Communications. 6:7391. doi:10.1038/ncomms8391
Published Date: June 2015
Demonstrates a novel CRISPR/Cas9 system that allows for generation of in utero loss of function mutation.
Generation of genetically engineered mouse models (GEMMs) has been the gold standard for validating relevant tumor suppressor genes (TSGs). These models are typically produced by generating knockout mutations via homologous recombination in mouse embryonic stem cells. The authors adapted a novel CRISPR/Cas9 system that allows for the generation of in utero loss of function mutations, which is a time- and cost-effective method for validating the recent influx of candidate cancer-related genes.